Research

Principal Investigator

National Natural Science Foundation of China (×1)

Open Funding Project of National Key Laboratory (×1)

Natural Science Basic Research Plan in Shaanxi Province of China (×1)

Xidian University Specially Funded Project for Interdisciplinary Exploration(×1)

Fundamental Research Funds for the Central Universities (×4)

Enterprise Collaborative Project (×1)

Participated

National Natural Science Foundation of China (×5)

Selected Publications

[1]Yun Zeng, Taotao Dou, Lei Ma, and Jingwen Ma*. Biomedical photoacoustic imaging for molecular detection and disease diagnosis: “always-on” and “turn-on” probes.Adv. Sci.,2022,9(25), 2202384.

[2]Yun Zeng*, Rachel L. Nixon, Wenyan Liu, and Risheng Wang*. The applications of functionalized DNA nanostructures in bioimaging and cancer therapy.Biomaterials,2021,268, 120560.

[3]Yun Zeng, Huifang Liu, Jingwen Ma, Ke Li, Pang Chang, Chenying Wang, Lei Li, Dan Chen, Changhu Liu, Na Li*, Wenhua Zhan*, and Yonghua Zhan*. Cobalt ferrite-gossypol coordination nanoagents with high photothermal conversion efficiency sensitizing chemotherapy against Bcl-2 to induce tumor apoptosis.Small,2023,19(34), 2300104.

[4]Yun Zeng, Yonghua Zhan*, Xinyue Liu, Jingwen Ma, Huifang Liu, Hanrui Li, Tong Yi, Qingxia Zhu, Getao Du, Linfei Zhao, Dan Chen, and Xueli Chen*. Highly efficient chemo/photothermal therapy alleviating tumor hypoxia against cancer and attenuate liver metastasis in vivo.Chem. Eng. J.,2022,448, 137724.

[5] Peng Chang, Yingying Guo, Dan Chen, Ke Li, Wei Wang, Zhihua Yang, Jingwen Ma*,Yun Zeng*, Wenhua Zhan*, Yonghua Zhan*. High-temperature PTT/CDT coordination nanoplatform realizing exacerbated hypoxia for enhancing hypoxia-activated chemotherapy to overcome tumor drug resistance.J. Nanobiotechnol.,2024,22, 374.

[6]Yun Zeng, Linfei Zhao, Ke Li, Jingwen Ma, Dan Chen, Changhu Liu, Wenhua Zhan*, and Yonghua Zhan*. Aptamer-functionalized nanoplatforms overcoming temozolomide resistance in synergistic chemo/photothermal therapy through alleviating tumor hypoxia.Nano Res.,2023,16(7), 9859-9872.

[7]Yun Zeng, Peng Chang, Jingwen Ma, Ke Li, Chunhong Zhang, Yingying Guo, Hanrui Li, Qingxia Zhu, Huifang Liu, Wenjing Wang, Yuwei Chen, Dan Chen, Xu Cao*, and Yonghua Zhan*. DNA origami-anthraquinone hybrid nanostructures for in vivo quantitative monitoring of the progression of tumor hypoxia affected by chemotherapy.ACS Appl. Mater. Interfaces,2022,14(5), 6387-6403.

[8] Jingwen Ma*, Na Li, Jingjian Wang, Zhe Liu, Yulong Han, andYun Zeng*. In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms.Exploration,2023,3(5), 20220161.

[9]Yun Zeng, Tong Yi, Jingwen Ma, Ming Han, Xinyi Xu, Dan Chen, Xueli Chen, Risheng Wang, and Yonghua Zhan*. Precisely controlled polydopamine-mediated antibacterial system: mathematical model of polymerization, prediction of antibacterial capacity, and promotion of wound healing.Nanotechnology,2022,33(45), 455102.

[10]Yun Zeng, Jiajun Liu, Shuo Yang, Wenyan Liu, Liang Xu, and Risheng Wang*. Time-lapse live cell imaging to monitor doxorubicin release from DNA origami nanostructures.J. Mater. Chem. B,2018,6(11), 1605-1612. (Front Cover, 2018 Journal of Materials Chemistry B HOT Papers)

Daocheng Wu, Jingwen Ma, Youshen Wu,Yun Zeng, Shihong Shen. CN 201510777717.1

Daocheng Wu, Ke Li, Jiajun Liu, Hao Liu,Yun Zeng. CN 201410668713.5

(1)Chinese Biomaterials Congress:2015 (Haikou), 2017 (Nanchang), 2019 (Dalian),2020 (Youth Forum, Beijing), 2023 (Chongqing)

(2)Chinese Society of Biomedical Engineering Conference & Medical Innovation Summit:2023 (Suzhou);Youth Forum of Chinese Society of Biomedical Engineering: 2019 (Dalian)

(3)International Symposium on Molecular Imaging (ISMI):2019 (Zhuhai)

(4)5th Symposium on Innovative Polymers for Controlled Delivery (SIPCD):2018 (Suzhou)

(5)Ozark Biomedical Initiative Research Symposium (OBIRS):2017 (Rolla)

Dr. Jingwen Ma, Ninth Hospital of Xi'an